In A 1st, Scientists Use Revolutionary Gene-Editing Tool To Edit Inside A Patient

https://www.npr.org/sections/health-shots/2020/03/04/811461486/in-a-1st-scientists-use-revolutionary-gene-editing-tool-to-edit-inside-a-patient

Cancer immunotherapy pioneers win medicine Nobel

http://www.sciencemag.org/news/2018/10/cancer-immunotherapy-pioneers-win-medicine-nobel

Bacterial injections into tumors show early promise for treating cancer

http://www.sciencemag.org/news/2018/10/bacterial-injections-tumors-show-early-promise-treating-cancer

Lutetium in the treatment of neuroendocrine tumours

Lutetium-labelled peptides for therapy of neuroendocrine tumours

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304065

Treatment with radiolabelled somatostatin analogues is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumours. Symptomatic improvement may occur with 177Lu-labelled somatostatin analogues that have been used for peptide receptor radionuclide therapy (PRRT). 

MR-Linac Radiation Therapy: new cancer treatment technology at Froedtert Hospital, Milwaukee

MR-Linac Radiation Therapy
-One of only two sites in the U.S. offering this capability.

Female patients with MEN1 are at increased risk for breast cancer

Breast-Cancer Predisposition in Multiple Endocrine Neoplasia Type 1

K. Dreijerink, P. Goudet, et al.
New England Journal of Medicine
N Engl J Med 2014; 371:583-584; August 7, 2014; DOI: 10.1056/NEJMc1406028

Notes:

• Intensified breast-cancer screening at a relatively young age should be considered in female patients with MEN1.
  

Primary Hyperparathyroidism in Young People. When Should We Perform Genetic Testing for MEN1?

Primary Hyperparathyroidism in Young People. When Should We Perform Genetic Testing for Multiple Endocrine Neoplasia 1 (MEN-1)?

T. Lassen, L. Friis-Hansen, et al.
The Journal of Clinical Endocrinology & Metabolism 2014 99:11, 3983-3987

Results and Discussion:

Whether to perform screening of patients with pHPT under the age of 30, 35, or 40 years is controversial. According to international guidelines from 2001, genetic testing is indicated only in patients with pHPT below the age of 30 years. However, in updated guidelines from 2012, it is suggested to perform genetic testing in patients with pHPT below the age of 30 years, but also at any age in patients presenting with multigland parathyroid disease.

Conclusions:

The reviewed literature and the presented case illustrate the importance of this change in international guidelines, but they also raise concern for a potential underdiagnosing of patients before year 2012.